CB2233 has new mechanism of action and cytoprotective and neuroprotective properties in vitro. The candidate exhibits significant activity in proof-of-concept models for memory loss. Even though CB2233 has a mechanism similar to CB8411, it differentiates itself by significantly reducing the Aß toxicity in transgenic nemotode worms, a model to investigate development of plaques by delaying paralysis in an Alzheimer’s disease model. The target indication includes dementia, cognitive deficits in Alzheimer’s disease and attention-deficit hyperactivity disorder (ADHD). The unique mechanism of action will be game-changing in the treatment of cognition disorders.